A carregar...
Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
We compared the cost-utility analysis for edoxaban at both doses with that of dabigatran at both doses, rivaroxaban, and apixaban (non vitamin K antagonist oral anticoagulants, NOAC) in a German population. Data of clinical outcome events were taken from edoxaban's ENGAGE-AF, dabigatran's...
Na minha lista:
| Publicado no: | Biomed Res Int |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Hindawi Publishing Corporation
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4380099/ https://ncbi.nlm.nih.gov/pubmed/25853142 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/876923 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|